These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 20724701)

  • 21. HDL--associated paraoxonase 1 (PON1) and dietary antioxidants attenuate lipoprotein oxidation, macrophage foam cells formation and atherosclerosis development.
    Aviram M
    Pathophysiol Haemost Thromb; 2006; 35(1-2):146-51. PubMed ID: 16855361
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme.
    Mahrooz A
    Curr Clin Pharmacol; 2016; 11(4):259-264. PubMed ID: 27633038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function.
    Sun JT; Yang K; Lu L; Zhu ZB; Zhu JZ; Ni JW; Han H; Chen N; Zhang RY
    Am J Physiol Renal Physiol; 2016 Mar; 310(6):F511-7. PubMed ID: 26764205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.
    Kim DS; Marsillach J; Furlong CE; Jarvik GP
    Pharmacogenomics; 2013 Sep; 14(12):1495-515. PubMed ID: 24024900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/dCas9 Transcriptional Activation of Endogenous Apolipoprotein AI and Paraoxonase 1 in Enterocytes Alleviates Endothelial Cell Dysfunction.
    Toma L; Barbălată T; Sanda GM; Niculescu LS; Sima AV; Stancu CS
    Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paired measurements of paraoxonase 1 and serum amyloid A as useful disease markers.
    Kotani K; Yamada T; Gugliucci A
    Biomed Res Int; 2013; 2013():481437. PubMed ID: 24228251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functionality of HDL: antioxidation and detoxifying effects.
    Karlsson H; Kontush A; James RW
    Handb Exp Pharmacol; 2015; 224():207-28. PubMed ID: 25522989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment.
    Marsillach J; Aragonès G; Beltrán R; Caballeria J; Pedro-Botet J; Morcillo-Suárez C; Navarro A; Joven J; Camps J
    Clin Biochem; 2009 Jan; 42(1-2):91-8. PubMed ID: 18977341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease.
    Mackness M; Durrington P; Mackness B
    Curr Opin Lipidol; 2004 Aug; 15(4):399-404. PubMed ID: 15243212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pcpe2: A New Partner for the Scavenger Receptor Class B Type I in High-Density Lipoprotein Selective Lipid Uptake.
    Trigatti BL
    Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2726-2729. PubMed ID: 34615373
    [No Abstract]   [Full Text] [Related]  

  • 31. Scavenger receptor B1 mutation, elevated HDL cholesterol and a paradoxical increase in atherosclerosis.
    Davidson J; Rotondo D
    Curr Opin Lipidol; 2016 Oct; 27(5):541-2. PubMed ID: 27579550
    [No Abstract]   [Full Text] [Related]  

  • 32. Revealing the Role of High-Density Lipoprotein in Colorectal Cancer.
    Zeljkovic A; Vekic J; Mihajlovic M; Gojkovic T; Vladimirov S; Zeljkovic D; Spasojevic-Kalimanovska V; Trifunovic B
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catalytic stimulation by restrained active-site floppiness--the case of high density lipoprotein-bound serum paraoxonase-1.
    Ben-David M; Sussman JL; Maxwell CI; Szeler K; Kamerlin SCL; Tawfik DS
    J Mol Biol; 2015 Mar; 427(6 Pt B):1359-1374. PubMed ID: 25644661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: The missing link between environmental and genetic regulation.
    Mahrooz A; Mackness M; Bagheri A; Ghaffari-Cherati M; Masoumi P
    Clin Biochem; 2019 Nov; 73():1-10. PubMed ID: 31351988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term stability of paraoxonase-1 and high-density lipoprotein in human serum.
    Beekhof PK; Gorshunska M; Jansen EH
    Lipids Health Dis; 2012 May; 11():53. PubMed ID: 22584062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A liver-high-density lipoprotein-ovarian axis of fertility.
    Attie AD
    Endocrinology; 2006 Apr; 147(4):1575-6. PubMed ID: 16543376
    [No Abstract]   [Full Text] [Related]  

  • 37. Functional validation of new pathways in lipoprotein metabolism identified by human genetics.
    Bauer RC; Stylianou IM; Rader DJ
    Curr Opin Lipidol; 2011 Apr; 22(2):123-8. PubMed ID: 21311327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the stoichiometric efficacy of mammalian expressed paraoxonase-1 variant I-F11 to afford protection against G-type nerve agents.
    Mata DG; Sabnekar P; Watson CA; Rezk PE; Chilukuri N
    Chem Biol Interact; 2016 Nov; 259(Pt B):233-241. PubMed ID: 27083144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chlorogenic acid protects paraoxonase 1 activity in high density lipoprotein from inactivation caused by physiological concentrations of hypochlorite.
    Gugliucci A; Bastos DH
    Fitoterapia; 2009 Mar; 80(2):138-42. PubMed ID: 19248222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-density lipoprotein-associated paraoxonase 1: a possible prognostic biomarker for heart failure?
    Rom O; Aviram M
    Eur J Heart Fail; 2017 Jun; 19(6):756-759. PubMed ID: 28371029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.